Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 1,146 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $179.10, for a total value of $205,248.60. Following the transaction, the vice president now directly owns 22,229 shares in the company, valued at $3,981,213.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

EW opened at $179.75 on Friday. The stock has a market cap of $36.45 billion, a PE ratio of 38.24, a P/E/G ratio of 2.26 and a beta of 0.90. Edwards Lifesciences Corp has a 52-week low of $123.00 and a 52-week high of $181.43. The company has a quick ratio of 1.92, a current ratio of 2.61 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.17. The company had revenue of $977.70 million during the quarter, compared to the consensus estimate of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same quarter in the prior year, the company posted $0.94 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corp will post 5.21 earnings per share for the current year.

EW has been the topic of a number of recent research reports. Canaccord Genuity boosted their target price on Edwards Lifesciences from $177.00 to $186.00 and gave the company a “positive” rating in a research note on Wednesday, January 16th. Raymond James boosted their target price on Edwards Lifesciences from $160.00 to $175.00 and gave the company an “outperform” rating in a research note on Thursday, December 6th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 target price on shares of Edwards Lifesciences in a research note on Sunday, February 3rd. Jefferies Financial Group boosted their target price on Edwards Lifesciences from $168.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday, December 6th. Finally, Cowen set a $190.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, November 30th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $171.10.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Executive Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $25,000. Sontag Advisory LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $26,000. Lindbrook Capital LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $27,000. Capital Financial Planning LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $28,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $30,000. Institutional investors own 83.29% of the company’s stock.

WARNING: This piece was posted by Marea Informative and is the property of of Marea Informative. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.mareainformativa.com/news/2019/03/17/edwards-lifesciences-corp-ew-vp-sells-205248-60-in-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Dividend Aristocrat Index

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.